NASDAQ:RENB Renovaro (RENB) Stock Price, News & Analysis $0.53 -0.01 (-1.84%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Renovaro Stock (NASDAQ:RENB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Renovaro alerts:Sign Up Key Stats Today's Range$0.53▼$0.6050-Day Range$0.41▼$0.9352-Week Range$0.40▼$5.25Volume174,091 shsAverage Volume551,820 shsMarket Capitalization$78.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewRenovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.Read More… Unveiled: NVIDIA’s "Secret Royalty" Program (Ad)Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?Click Here to learn how to get in now >>> Renovaro Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks36th Percentile Overall ScoreRENB MarketRank™: Renovaro scored higher than 36% of companies evaluated by MarketBeat, and ranked 800th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Renovaro.Read more about Renovaro's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Renovaro is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Renovaro is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRenovaro has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Renovaro's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.75% of the float of Renovaro has been sold short.Short Interest Ratio / Days to CoverRenovaro has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Renovaro has recently decreased by 7.41%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRenovaro does not currently pay a dividend.Dividend GrowthRenovaro does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.75% of the float of Renovaro has been sold short.Short Interest Ratio / Days to CoverRenovaro has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Renovaro has recently decreased by 7.41%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News Sentiment0.29 News SentimentRenovaro has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Renovaro this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Renovaro to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Renovaro insiders have not sold or bought any company stock.Percentage Held by Insiders21.72% of the stock of Renovaro is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.41% of the stock of Renovaro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Renovaro's insider trading history. Receive RENB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Renovaro and its competitors with MarketBeat's FREE daily newsletter. Email Address RENB Stock News HeadlinesRenovaro BioSciences files $200M mixed securities shelfOctober 31 at 9:12 AM | markets.businessinsider.comRenovaro (NASDAQ:RENB) Stock Price Down 4% - Time to Sell?October 30 at 2:29 AM | americanbankingnews.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 31, 2024 | Porter & Company (Ad)Renovaro Names Weinstein as CEO; Four New Board AppointmentsOctober 18, 2024 | marketwatch.comRenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore SequencingOctober 17, 2024 | globenewswire.comRenovaro Inc: Renovaro Announces Strategic Restructuring and Leadership TransitionOctober 17, 2024 | finanznachrichten.deRenovaro Announces Strategic Restructuring and Leadership TransitionOctober 16, 2024 | globenewswire.comRenovaro (NASDAQ:RENB) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comSee More Headlines RENB Stock Analysis - Frequently Asked Questions How have RENB shares performed this year? Renovaro's stock was trading at $3.17 at the beginning of the year. Since then, RENB shares have decreased by 83.2% and is now trading at $0.5321. View the best growth stocks for 2024 here. How were Renovaro's earnings last quarter? Renovaro Inc. (NASDAQ:RENB) released its quarterly earnings data on Thursday, October, 10th. The company reported ($0.45) earnings per share for the quarter. How do I buy shares of Renovaro? Shares of RENB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Renovaro own? Based on aggregate information from My MarketBeat watchlists, some other companies that Renovaro investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW). Company Calendar Last Earnings10/10/2024Today10/31/2024Next Earnings (Estimated)11/12/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RENB CUSIPN/A CIK1527728 Webwww.enochianbio.com Phone305-918-1980FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-80,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-80.99% Return on Assets-63.25% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.89 per share Price / Book0.60Miscellaneous Outstanding Shares147,505,000Free Float122,269,000Market Cap$78.49 million OptionableOptionable Beta0.56 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (NASDAQ:RENB) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renovaro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Renovaro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.